---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000207"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:20:35.358645+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site

## Summary
- FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.
- Raxibacumab is a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
- Approval supports multi-year turnaround strategy to consolidate manufacturing in Winnipeg and Lansing.
- Winnipeg facility has over 45 years experience in commercial therapeutics manufacturing.
- CEO Joe Papa says this regulatory action advances flexible, streamlined manufacturing network.

## SEC filing metadata
- accession: 0001367644-25-000207
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/0001367644-25-000207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/ebs-20251212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000207
- JSON: https://secwatch.observer/filing/0001367644-25-000207.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.